Thomas Knopp, DO
Internal Medicine · Lexington, KYNPI 1093998239
Payments from drug & device makers
Across 252 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$558
- QOL Medical, LLC$537
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$427
- Sanofi$274
- Takeda Pharmaceuticals U.S.A., Inc.$231
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$4009%
- Food & beverage$3,73588%
- Education$972%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 85 | $1,048 |
| Johnson & Johnson | 39 | $558 |
| QOL Medical, LLC | 8 | $537 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $427 |
| Sanofi | 16 | $274 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $231 |
| Gilead | 8 | $176 |
| Regeneron Healthcare Solutions, Inc. | 5 | $137 |
| Lilly USA, LLC | 6 | $124 |
| Phathom Pharmaceuticals, Inc. | 5 | $117 |
| Bristol Myers Squibb | 7 | $94 |
| Vivus LLC | 3 | $68 |
| Ferring Pharmaceuticals Inc. | 4 | $68 |
| Pfizer | 4 | $63 |
| Nestle Healthcare Nutrition Inc. | 3 | $49 |
| Covidien LP | 1 | $41 |
| Merck | 2 | $35 |
| TELA Bio, Inc. | 2 | $31 |
| Braintree Laboratories, Inc. | 2 | $30 |
| Axonics, Inc. | 2 | $28 |
| Shire North American Group Inc | 2 | $27 |
| Redhill Biopharma Inc. | 1 | $23 |
| Celltrion USA Inc. | 1 | $16 |
| UCB, Inc. | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sucraid$400
How this compares
$4,232 in reported general payments places this provider in the 85th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 43 | $125,707 |
| Humira(Cf) PenAdalimumab | 13 | $88,194 |
| Humira(Cf)Adalimumab | 12 | $85,148 |
| CreonLipase/Protease/Amylase | 14 | $76,984 |
| LinzessLinaclotide | 77 | $75,603 |
| RelistorMethylnaltrexone Bromide | 20 | $67,670 |
| TrulancePlecanatide | 23 | $25,995 |
| MotegrityPrucalopride Succinate | 30 | $23,485 |
| Alosetron Hcl | 28 | $14,834 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 77 | $12,830 |
| VoqueznaVonoprazan Fumarate | 20 | $12,571 |
| Colestipol Hcl | 79 | $8,318 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 113 | $7,321 |
| MovantikNaloxegol Oxalate | 11 | $6,952 |
| NexiumEsomeprazole Magnesium | 11 | $5,895 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Creon, Linzess | $1,048 | $237,735103 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Trulance | $427 | $219,37286 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $231 | $23,48530 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $68 | $12,83077 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $117 | $12,57120 claims |
| Redhill Biopharma Inc.Movantik | $23 | $6,95211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Lexington
- Neil FarrisLexington$3M
- David ManninoLexington$168K
- John BordersLexington$166K
- Fadi BachaLexington$31K
- James BordersLexington$31K
- Jad BalloutLexington$30K
- Thomas von UnrugLexington$22K
- Danilo CoralesLexington$17K
- Mohamed TashaniLexington$17K
- Kelli TrentLexington$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.